EMA Withdrawn: Irbesartan Hydrochlorothiazide BMS (irbesartan;hydrochlorothiazide) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

The EMA withdrawal of irbesartan/hydrochlorothiazide (BMS) from the European market in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Irbesartan/Hydrochlorothiazide (irbesartan/hydrochlorothiazide)

Snippet

Status: Withdrawn. Therapeutic area: Hypertension. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 09/10/2009